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Abstract 
Background: Mortality attributable to heart failure remains high. The prevalence of heart failure in patients with 
diabetes mellitus ranges from 19 to 26%. It is estimated that up to 21.1 million adults in the United States have diag‑
nosed diabetes mellitus and around 80.8 million have impaired fasting glucose. We investigated the associations of 
fasting glucose (FG) and fasting insulin (FI), the homeostasis model assessment‑insulin resistance index (HOMA‑IR) 
and 2‑h postload glucose (2HG) and insulin (2HI) with parameters of left ventricular geometry and function and arte‑
rial stiffness determined by magnetic resonance imaging in individuals without diagnosed type 2 diabetes.
Methods: Cross‑sectional analyses of 1001 individuals (453 women, 45.3%), aged 21 to 80 years, from two independ‑
ent population‑based studies, the Study of Health in Pomerania (SHIP‑TREND‑0) and KORA FF4 Study. FG, FI, HOMA‑IR, 
2HG and 2HI, as well as glucose tolerance categories, were analyzed for associations with heart and arterial param‑
eters using multivariable‑adjusted linear regression models.
Results: In total, 390 individuals (39%) had prediabetes (isolated impaired fasting glucose, isolated glucose toler‑
ance or both), and 49 (4.9%) were found to have unknown type 2 diabetes. In the multivariable‑adjusted analysis, 
positive linear associations of FG, FI, HOMA‑IR, 2HG and 2HI with arterial stiffness index and left ventricular wall‑
thickness and concentricity and inverse linear associations with left ventricular end‑diastolic volume were observed. 
A 1 mmol/l higher FG was associated with a 1.18 ml/m2.7 (1.80 to 0.57; p < 0.001) lower left ventricular end‑diastolic 
volume index, a 0.042 mm/m2.7 (0.014 to 0.070) higher left ventricular wall‑thickness index, a 0.12 mmHg m2.7/ml 
(0.06 to 0.17; p < 0.001) greater arterial stiffness index and a 0.037 g/ml (0.018 to 0.056; p < 0.001) higher left ventricular 
concentricity.
Conclusions: Our findings suggest that higher glucose levels in the prediabetic range and insulin resistance might 
lead to higher arterial stiffness and concentric remodeling of the heart.
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Introduction
The leading cause of death in patients with type 2 diabe-
tes is cardiovascular disease. Moreover, the risk of car-
diovascular mortality is doubled when compared with 
individuals without type 2 diabetes [1]. One of the major 
cardiovascular complications of type 2 diabetes is heart 
failure with a prevalence that ranges from 19 to 26% 
among patients with diabetes mellitus [2]. In line with 
these observations, the term diabetic cardiomyopathy 
was defined as a left ventricular dysfunction that occurs 
in diabetic patients in the absence of coronary athero-
sclerosis and hypertension [2]. The initial stage of the 
diabetic cardiomyopathy is characterized by subclinical 
changes of the cardiac geometry and marginal changes 
in diastolic function. A previous analysis [3] of our group 
showed that 43.1% of adults in the northeast and 30.1% 
in the south of Germany already presented glucose levels 
that fulfill the criteria of prediabetes. Importantly, previ-
ous studies [4–7] already showed subclinical alterations 
in cardiac structure and function not just in patients with 
type 2 diabetes, but already in individuals with prediabe-
tes. Otherwise, the results of these studies are sometimes 
contradictory regarding their findings. While a previ-
ous study of the Multiethnic Study of Atherosclerosis 
(MESA) [4] showed that individuals with impaired fast-
ing glucose (IFG) had no significant difference regarding 
left ventricular mass (LVM), when compared with indi-
viduals with normal fasting glucose, a more recent anal-
ysis of the same cohort [5] demonstrated that subjects 
with IFG had a higher LVM. Contrary to that, an analysis 
from the Framingham Heart Study [6], showed that the 
homeostasis model assessment-insulin resistance index 
(HOMA-IR) was inversely related with the LVM.
The aim of the present study was to investigate the 
associations of parameters from an oral glucose tolerance 
test (OGTT), as well as the presence of prediabetes and 
unknown type 2 diabetes (UT2D), with indicators of the 
left ventricular (LV) geometry and function and arterial 
stiffness as determined by magnetic resonance imaging 
(MRI) using data from two population-based samples 
from the Northeastern and Southern part of Germany.
Materials and methods
Pooled study sample
The present cross-sectional study is based on data from 
two independent population-based investigations, the 
Study of Health in Pomerania (SHIP-TREND-0) [8, 9] 
and the Cooperative Health Research in the Region of 
Augsburg (KORA FF4) [10]. Our pooled sample, from 
SHIP-TREND-0 and KORA FF4, comprised 1391 indi-
viduals (604 women, 43.4%) aged 21 to 81  years. Indi-
viduals with inadequate MRI image quality (n = 79), 
previous myocardial infarction or stroke (n = 16), left 
ventricular ejection fraction (determined by MRI) less 
than 40% (n = 9), fasting time less than 8 h (n = 217), 
use of hypoglycemic medication (n = 37), missing val-
ues for OGTT parameters (n = 17) or any of the covari-
ates (n = 9) as well as individuals with extreme values 
(> 99.5th percentile for fasting glucose, insulin or 2-h 
postload glucose; n = 6) were excluded. Accordingly, our 
final analytical sample consisted of 1001 individuals (453 
women, 45.3%), aged 21 to 80 years.
All study participants gave written informed consent. 
The study was approved by the ethics committees of the 
University of Greifswald, the Bavarian Chamber of Physi-
cians, and the Ludwig-Maximilians-Universität München 
and complies with the Declaration of Helsinki.
Glucose and insulin measurements, oral glucose tolerance 
test and classification of prediabetes and unknown type 2 
diabetes
Measurements of fasting glucose (FG) and 2-h postload 
glucose (2HG) were based on plasma in SHIP-TREND-0 
and on serum in KORA FF4. Duplicate measure-
ments were carried out using serum samples from all 
SHIP-TREND-0 participants and serum glucose from 
KORA FF4 and plasma glucose from SHIP-TREND-0 
were considered as comparable for the current analy-
sis (concordance correlation coefficient of r = 0.94 in a 
validation study comparing plasma and serum glucose 
measurements).
In both studies, FG was sampled and 75 g of anhydrous 
glucose (Dextro OGT; Boehringer Mannheim, Man-
nheim, Germany) was given to those participants with-
out diagnosed type 2 diabetes or taking glucose-lowering 
agents. In SHIP-TREND-0, plasma FG and 2HG levels 
were measured using a hexokinase method (Dimen-
sion Vista 1500, Siemens Healthcare Diagnostics, Esch-
born, Germany) [3] and serum fasting insulin (FI) and 
2-h postload glucose insulin (2HI) values were assessed 
by an electrochemiluminescence immunoassay (ADVIA 
Centaur, Siemens Healthcare Diagnostics, Eschborn, 
Germany) [11]. In KORA FF4, serum FG and 2HG levels 
were measured using an enzymatic colorimetric method 
(Dimension Vista 1500, Siemens Healthcare Diagnostics, 
Eschborn, Germany or Cobas c702, Roche Diagnostics 
GmbH, Mannheim, Germany) and FI and 2HI values 
were measured by a solid-phase enzyme-labeled chemi-
luminescent immunometric assay (Immulite 2000 Xpi, 
Siemens Healthcare Diagnostics, Eschborn, Germany) or 
by an electrochemiluminescence immunoassay (Cobas e 
602, Roche Diagnostics GmbH, Mannheim, Germany).
The homeostasis model assessment-insulin resistance 
index (HOMA-IR) was calculated as (FG [mmol/l] × FI 
[μU/ml])/22.5 [12].
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Following the criteria of the American Diabetes Asso-
ciation (ADA) [13], we classified individuals as having 
normal glucose tolerance (NGT) when they had FG val-
ues < 5.6  mmol/l (< 100  mg/dl) and 2HG < 7.8  mmol/l 
(< 140  mg/dl). Unknown type 2 diabetes (UT2D) was 
defined as FG values ≥ 7.0  mmol/l (≥ 126  mg/dl) or 
2HG ≥ 11.1 mmol/l (≥ 200 mg/dl). Participants were clas-
sified as having prediabetes if FG values were between 
5.6 and 6.9  mmol/l (100–125  mg/dl, impaired fasting 
glucose: IFG) and/or 2HG values were between 7.8 and 
11.0 mmol/l (140–199 mg/dl, impaired glucose tolerance: 
IGT) [3, 13]. We defined three groups of prediabetes: iso-
lated impaired fasting glucose (i-IFG), isolated impaired 
glucose tolerance (i-IGT), and combined IFG and IGT 
(IFG + IGT) [3, 13].
Cardiac MR imaging
In SHIP-TREND-0, cardiac MR imaging was performed 
on a 1.5 Tesla MR system (Magnetom Avanto; Siemens 
Medical Systems, Erlangen, Germany) [11, 14] and in 
KORA FF4, on a 3 Tesla MR system (Magnetom Skyra; 
Siemens Medical Systems, Erlangen, Germany) [15, 16]. 
In both studies imaging of cardiac function and morphol-
ogy was performed using cine steady-state free preces-
sion (cine-SSFP) sequences.
Image analysis
LV end-diastolic volume (LVEDV) was determined dur-
ing the first image of the acquisition. LV end-systolic vol-
ume (LVESV) was measured by determining the phase in 
which the LV intra-cavity blood pool was at its smallest 
by visual assessment at the midventricular level. LV myo-
cardial mass (LVM) was calculated at the end-diastole 
using the specific density of the myocardium (1.05 g/cm3) 
[14]. Papillary muscles were included in the LVM and 
excluded of the LV end-diastolic and systolic volumes. 
Basal slices were included if at least half of the LV circum-
ference blood pool was confined by myocardium [17]. 
Inclusion or exclusion of apical slices depended on the 
visibility of myocardium. LV wall-thickness (LVWT) was 
determined in the 16-segment model (according to the 
AHA-segment model) [18]. LV concentricity (LVC) was 
calculated as LVM/LVEDV. LV stroke volume (LVSV), LV 
cardiac output (LVCO) and LV ejection fraction (LVEF) 
were calculated following the formulas below:
LVM, LVEDV, LVESV, LVWT, LVSV and LVCO were 
indexed for body height in meters, normalized to the 
LVSV (ml) = LVEDV − LVESV
LVCO (l/min) = LVSV × heart rate
LVEF (%) = (LVEDV − LVESV) / LVEDV
allometric power of 2.7, which linearizes the relations 
between the cardiac anatomic and functional parameters 
with height and identifies the impact of obesity [19]. This 
resulted in LVM index (LVMI), LVEDV index (LVEDVI), 
LVESV index (LVESVI), LVWT index (LVWTI), LVSV 
index (LVSI) and LVCO index (LVCI).
Arterial stiffness index (ASI) was calculated as (systolic 
blood pressure − diastolic blood pressure)/LVSI [20].
Interview, medical and laboratory examinations
In both studies, information on socio-economic vari-
ables (including years of school education [< 10, 10, 
or > 10 years]), smoking status (never, former or current 
smoker) [21], alcohol consumption (in grams per day) 
and medical history was collected by trained and certifi-
cated medical staff during a standardized interview. Sed-
entary lifestyle was defined as individuals who did not 
participate in leisure time exercise, for at least 1 h/week, 
during summer or winter [22]. Participants were asked 
to bring the original packaging of their medications that 
were taken during the last 7 days before the examination 
date. Unique identifiers and drug names were recorded 
according to the ATC classification system.
All participants underwent an extensive standardized 
medical examination. Anthropometric measurements 
included height and weight based on recommendations 
of the World Health Organization (WHO) [23]. Weight 
was measured to the nearest 0.1 kg in light clothing and 
without shoes using standard digital scales. Body mass 
index (BMI) was calculated as weight (kg)/height2  (m2). 
Waist circumference (WC) was measured to the nearest 
0.1 cm using an inelastic tape midway between the lower 
rib margin and the iliac crest in the horizontal plane, with 
the participant standing comfortably with weight distrib-
uted evenly on both feet [24]. While in SHIP-TREND-0 
body fat-free mass (FFM) and fat mass (FM) were meas-
ured by bioelectrical impedance analysis (BIA) using a 
multifrequency Nutriguard-M device (Data Input, Pöck-
ing, Germany) and the NUTRI4 software (Data Input, 
Pöcking, Germany) [25–27], in KORA FF4, BIA scans 
were obtained by BIA 2000-S device (Data Input, Pöck-
ing, Germany) with an operating frequency of 50 kHz at 
0.8 mA. Ohmic resistance was measured at the dominant 
hand (between wrist and dorsum) and the dominant foot 
(between angle and dorsum).
After a resting period of at least 5  min, systolic and 
diastolic blood pressures as well as heart rate were meas-
ured three times on the right arm of seated subjects 
using an oscillometric digital blood pressure monitor 
(HEM-705CP, Omron Corporation, Tokyo, Japan) with 
an interval of 3 min between readings. The mean of the 
second and third measurements was used for the pre-
sent analyses. Antihypertensive medication was defined 
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as use of agents with the ATC-code C02, C03, C07, 
C08 and C09 [28]. Hypertension was defined as systolic 
blood pressure ≥ 140 mmHg and/or diastolic blood pres-
sure ≥ 90 mmHg and/or current self-reported use of any 
anti-hypertensive medications.
Fasting blood samples were obtained from all study 
participants while sitting [29]. In SHIP-TREND-0, gly-
cated hemoglobin was determined by high-performance 
liquid chromatography (Diamat, Bio-Rad Laboratories, 
Munich, Germany). Total serum cholesterol, low-density 
lipoprotein cholesterol (LDL-C) and high-density lipo-
protein cholesterol (HDL-C) were measured photometri-
cally (Dimension RxL or Dimension VISTA 1500, Siemens 
Healthcare Diagnostics, Eschborn, Germany). Serum 
creatinine concentration was assessed using a modified 
kinetic Jaffé method (Dimension RxL or Dimension Vista 
1500, Siemens Healthcare Diagnostics, Eschborn, Ger-
many). In KORA FF4, glycated hemoglobin was measured 
in hemolyzed whole blood using the cation-exchange high 
performance liquid chromatographic, photometric VARI-
ANT II TURBO HbA1c Kit-2.0 assay on a VARIANT II 
TURBO Hemoglobin Testing System (Bio-Rad Labora-
tories Inc., Hercules, USA). Total serum cholesterol, low-
density lipoprotein cholesterol (LDL-C), high-density 
lipoprotein cholesterol (HDL-C) and serum creatinine con-
centrations were measured using an enzymatic colorimet-
ric method (Dimension Vista 1500, Siemens Healthcare 
Diagnostics, Eschborn, Germany or Cobas c702, Roche 
Diagnostics GmbH, Mannheim, Germany). Because of the 
changes from Siemens to Roche, the Siemens measure-
ment results were calibrated to the Roche measurements 
using the following formulas (in mg/dl): Total_Choles-
terol_Roche = 3.00 + (Total_Cholesterol_Siemens  *  1.00); 
HDL_Cholesterol_Roche =  2.40 +  (HDL_Choles-
terol_Siemens  *  1.12); LDL_Cholesterol_Roche = antilog 
(−  0.13328 + [log LDL_Cholesterol_Siemens  *  1.03051]); 
Creatine_Roche = −  0.037568 + (Creatinine_Sie-
mens * 1.02703) [16].
Hypercholesterolemia was defined as use of lipid-
lowering medication defined by the ATC-code C10 
and/or total serum cholesterol ≥ 6.2  mmol/l and/or 
LDL-C ≥ 4.1  mmol/l and/or total cholesterol/HDL-C 
ratio ≥ 5.0. The estimated glomerular filtration rate was 
estimated according to the CKD-EPI formula [30] and 
expressed in ml/min/1.73 m2.
Statistical analysis
To characterize the study population, data was reported 
as median (with 25th and 75th percentiles) for continu-
ous variables and as percentages for categorical variables 
stratified by OGTT classification.
We used linear regression models to associate FG, FI, 
HOMA-IR, 2HG and 2HI levels and OGTT groups with 
LVMI, LVEDVI, LVESVI, LVWTI, LVC, ASI, LVSI, HR, 
LVCI and LVEF. The basic multivariable models were 
adjusted for age, sex, body fat-free mass and body fat 
mass (both assessed by BIA), systolic blood pressure, use 
of antihypertensive medication, smoking status, alcohol 
consumption, sedentarism (defined as individuals who 
did not participate in leisure time exercise for at least 1 h/
week during summer or winter [22]), estimated glomeru-
lar filtration rate, fasting time and study sample (SHIP-
TREND-0, KORA FF4). We used fractional polynomials 
to test potential non-linear relationships between expo-
sure and outcomes [31].
A two-sided p-value p < 0.05 was considered as statis-
tically significant. Statistical analyses were performed 
using Stata 14.2 (Stata Corporation, College Station, TX, 
USA).
Please see Additional file  1 for a more detailed 
description.
Results
Among the total study sample of 1001 individuals (453 
women, 45.3%), aged 21 to 80  years, 39.0% of the sub-
jects had prediabetes (isolated IFG, isolated IGT and 
combined IFG and IGT). Out of all prediabetes subjects, 
60.8% had isolated IFG, 23.1% had combined IFG and 
IGT and 16.1% had isolated IGT. In addition, the per-
centage of individuals with UT2D was 4.9%.
Table  1 shows the clinical characteristics of the study 
sample stratified by OGTT classification. Individuals 
with NGT were younger, more likely female, had a lower 
body mass index (BMI), body fat-free mass, fat mass and 
waist circumference and were less likely to have a history 
of hypertension and hypercholesterolemia, with a con-
comitant less frequent use of antihypertensive and lipid-
lowering medication. They also had higher eGFR and 
were more often current smokers.
Associations of FG, FI, HOMA‑IR, 2HG and 2HI 
and the OGTT groups with LV geometry
In multivariable-adjusted regression analyses, we 
found no significant associations of FG, FI, HOMA-
IR, 2HG and 2HI and the OGTT groups with 
LVMI (Additional file  1: Figure S1 and Table  2). We 
observed inverse linear associations of FG and 2HG 
with both LVEDVI and LVESVI, while FI, HOMA-IR 
and 2HI were inversely associated with these out-
comes in a log-linear fashion. A 1 mmol/l higher FG 
was associated with a 1.18  ml/m2.7 (95% confidence 
interval: 0.57 to 1.80; p < 0.001) smaller LVEDVI and a 
0.48 ml/m2.7 (0.12 to 0.84; p = 0.008) smaller LVESVI. 
We observed that the NGT group had larger LVEDVI 
and LVESVI mean values than the other groups, 
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while in the group with UT2D adjusted mean values 
for LVEDVI and LVESVI were the smallest volumes 
(Fig.  1 and Additional file  1: Figure S2 and Table  2). 
In addition, we found positive linear associations of 
FG, FI, HOMA-IR, 2HG and 2HI with LVWTI. A 
1 mmol/l higher FG was associated with a 0.042 mm/
m2.7 (0.014 to 0.070; p = 0.003) higher LVWTI. The 
NGT group had the lowest LVWTI mean value and 
the UT2D group the largest one (Fig. 2 and Table 2). 
Finally, we also observed significant positive lin-
ear associations of FG, FI, HOMA-IR, 2HG and 2HI 
with LVC. A 1 mmol/l higher FG was associated with 
a 0.037  g/ml (0.018 to 0.056; p < 0.001) higher LVC. 
The UT2D group had the greatest mean adjusted LVC 
value (Fig. 3 and Table 2).
Associations of FG, FI, HOMA‑IR, 2HG and 2HI 
and the OGTT groups with arterial stiffness and LV systolic 
function
In multivariable-adjusted regression analyses, we found 
significant positive linear associations of FG, FI, HOMA-
IR and 2HG with ASI while no such association was 
observed for 2HI. A 1 mmol/l higher FG was associated 
with a 0.12 mmHg m2.7/ml (0.06 to 0.17; p < 0.001) higher 
ASI. Moreover, the UT2D group had the greatest mean 
ASI value (Fig.  4 and Table  3). On the other hand, we 
Table 1 Characteristics of the study sample stratified by oral glucose tolerance test (OGTT) classification: normal glucose 
tolerance (NGT), isolated impaired fasting glucose (i-IFG), isolated impaired glucose tolerance (i-IGT), combined IFG 
and IGT (IFG + IGT) and unknown type 2 diabetes (UT2D)
Data are medians (25th, 75th percentile) or percentage
Italic values indicate significance of p-value < 0.05
* p-values are based on the Chi-squared test for categorical variables and the Wilcoxon rank-sum (or Mann–Whitney) tests for continuous variables
Parameter NGT i‑IFG i‑IGT IFG + IGT UT2D p‑value*
N (%) 562 (56.1) 237 (23.7) 63 (6.29) 90 (8.99) 49 (4.90)
Age (years) 47 (39, 57) 55 (46, 62) 51 (41, 62) 60 (52, 66) 61 (54, 68) < 0.001
Women (%) 52.7 32.5 55.6 31.1 34.7 < 0.001
Fasting serum glucose (mmol/l) 5.1 (4.9, 5.3) 5.9 (5.7, 6.2) 5.2 (4.9, 5.4) 6.0 (5.7, 6.3) 7.2 (6.3, 7.5) < 0.001
2‑h postload serum glucose (mmol/l) 5.3 (4.6, 6.2) 6.0 (5.4, 6.8) 8.4 (8.1, 9.1) 8.8 (8.2, 9.5) 11.6 (10.1, 13.9) < 0.001
Fasting insulin (µlU/ml) 7.3 (5.2, 9.8) 10.7 (7.3, 14.9) 12.3 (7.1, 15.6) 14.4 (10.8, 19.0) 18.1 (13.5, 26.2) < 0.001
2‑h postload insulin (µlU/ml) 37.0 (24.0, 57.0) 50.0 (32.0, 73.9) 97.6 (68.0, 160) 131 (75.5, 167) 132 (91.0, 187) < 0.001
Homeostasis model assessment‑insulin resistance 
index (HOMA‑IR)
1.65 (1.18, 2.25) 2.76 (1.91, 4.03) 2.69 (1.68, 3.63) 3.76 (2.86, 5.19) 5.71 (3.51, 7.94) < 0.001
Glycated hemoglobin (%) 5.2 (4.9, 5.4) 5.4 (5.2, 5.6) 5.3 (4.9, 5.6) 5.6 (5.2, 5.9) 6.0 (5.5, 6.4) < 0.001
Estimated glomerular filtration rate (ml/min/1.73 m2) 93.9 (84.0, 103) 89.5 (79.8, 97.4) 87.7 (79.0, 100) 84.9 (73.6, 96.3) 88.1 (79.9, 96.1) < 0.001
Smoking (%)
Never 40.8 38.4 41.3 40.0 49.0
Current 23.5 18.6 11.1 14.4 14.3
Former 35.8 43.0 47.6 45.6 36.7 0.080
Alcohol consumption (g/day) 4.25 (1.06, 13.4) 8.79 (2.69, 22.9) 2.90 (0.34, 12.9) 6.33 (1.45, 17.8) 4.69 (1.14, 12.9) 0.003
Weight (kg) 76.2 (65.8, 85.4) 84.4 (75.8, 94.0) 81.9 (74.3, 95.0) 89.3 (77.5, 96.1) 90.9 (81.2, 98.5) < 0.001
Height (cm) 171 (164, 179) 174 (165, 180) 170 (164, 175) 172 (167, 178) 173 (165, 176) 0.064
Body mass index (kg/m2) 25.5 (23.3, 28.4) 28.1 (25.8, 30.7) 28.9 (26.6, 32.1) 29.3 (27.1, 31.7) 31.1 (27.7, 33.1) < 0.001
Body fat‑free mass (kg) 52.5 (45.4, 64.2) 61.1 (51.6, 68.1) 55.7 (50.0, 60.8) 63.7 (53.2, 68.3) 61.3 (51.9, 68.1) < 0.001
Body fat mass (kg) 20.5 (16.5, 26.1) 23.8 (19.5, 29.2) 28.8 (20.3, 33.9) 25.6 (20.9, 32.2) 29.0 (23.2, 34.3) < 0.001
Waist circumference (cm) 86.2 (78.0, 95.2) 96.0 (88.1, 104) 94.5 (89.5, 106) 101 (94.0, 109) 104 (93.2, 112) < 0.001
Systolic blood pressure (mmHg) 120 (109, 130) 126 (116, 137) 128 (113, 139) 133 (123, 144) 137 (126, 150) < 0.001
Diastolic blood pressure (mmHg) 74.0 (68.0, 80.0) 77.5 (72.5, 83.5) 78.5 (72.5, 86.0) 81.5 (75.0, 89.0) 80.5 (72.5, 86.5) < 0.001
Hypertension (%) 23.1 45.2 52.4 67.8 77.6 < 0.001
Antihypertensive medications (%) 14.1 33.3 25.4 44.4 55.1 < 0.001
Total cholesterol (mmol/l) 5.40 (4.80, 6.07) 5.60 (5.00, 6.38) 5.70 (4.90, 6.07) 4.16 (3.58, 4.80) 5.70 (4.90, 6.50) < 0.001
Hypercholesterolemia (%) 32.7 51.9 44.4 54.4 57.1 < 0.001
Lipid‑lowering medication (%) 4.27 10.6 14.3 3.33 18.4 < 0.001
Sedentarism (%) 30.4 32.5 33.3 36.7 38.8 0.619
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observed significant inverse linear associations of FG, FI, 
HOMA-IR and 2HG with LVSI, while 2HI was inversely 
associated with this outcome in a log-linear fashion. A 
1  mmol/l higher FG was associated with a 0.71  ml/m2.7 
(0.31 to 1.11; p = 0.001) lower LVSI. We also found that 
while the NGT group had the largest LVSI mean value 
than the other groups, the UT2D had the smallest one 
(Fig. 5 and Table 3). Alternatively, we saw positive linear 
associations of FG, FI, HOMA-IR, 2HG and 2HI with 
HR. The NGT group had the lowest HR mean value and 
the UT2D group the highest one (Additional file 1: Fig-
ure S3 and Table  3). Finally, we did not find significant 
associations of FG, FI, HOMA-IR, 2HG and 2HI and the 
OGTT groups with LVCI and just an isolated positive 
linear association of 2HI with LVEF. All the other asso-
ciations with LVEF were not significant (Additional file 1: 
Figures S4, S5 and Table 3).
Discussion
In our analyses we found inverse associations of FG, FI, 
HOMA-IR, 2HG and 2HI with LVEDVI in individuals 
without known diabetes. FG mainly represents nocturnal 
hepatic gluconeogenesis dependent on hepatic insulin 
sensitivity and 2HG mainly reflects postprandial hyper-
glycemia. Conversely, we found positive linear associa-
tions of these glycemic variables with LVWTI. The net 
result of the associations of higher values of glycemic 
indicators on the left ventricular geometry was a greater 
left ventricular concentricity. This concentric remod-
eling was independent of other determinants, such as 
hypertension.
Noteworthy, the higher values of the glycemic vari-
ables were also accompanied by greater values of ASI and 
lower values of LVSI. The higher values of HR observed 
in association with the greater values of the glycemic 
variables might be a compensatory mechanism, for the 
lower LVSI, trying to avoid any deleterious consequence 
on the LVCI which was, in reality, not affected as well as 
the LVEF. This means that subjects with higher values of 
the glycemic variables would have a smaller “reserve”, in 
this circumstance heart rate, to utilize under stress when 
compared with individuals with lower levels.
In summary, our findings showed a direct relation 
between higher glucose and/or insulin levels and greater 
arterial stiffness, smaller LV chamber size and higher LV 
thickness with resultant LV concentric remodeling and 
lower LV stroke volume. These changes in heart geom-
etry and function may be related to the development of 
heart failure with preserved ejection fraction (HFpEF).
In the context of the published literature
A previous analysis of the Multiethnic Study of Athero-
sclerosis (MESA) [4] showed that individuals with IFG 
had smaller LVEDV and LVSV and no significant differ-
ence regarding LVM, LVCO and LVEF, when compared 
with normoglycemic subjects. When diabetic subjects 
Table 2 Adjusted* β-coefficient (95% confidence interval [CI]) of  the  associations between  fasting glucose (FG) 
and  insulin (FI), the  homeostasis model assessment-insulin resistance index (HOMA-IR) and  2-h postload glucose 
(2HG) and  insulin (2HI) with  left ventricular mass index (LVMI), left ventricular end-diastolic volume index (LVEDVI), 
left ventricular end-systolic volume index (LVESVI), left ventricular wall-thickness index (LVWTI) and  left ventricular 
concentricity (LVC)
Italic values indicate significance of p-value < 0.05
* Linear regression adjusted for age, sex, body fat-free mass, body fat mass, systolic blood pressure, use of antihypertensive medication, smoking status, alcohol 



















β‑coefficient (95% CI), 
p‑value
(n = 984)
Left ventricular mass 
index (g/m2.7)
− 0.08 (− 0.58 to 0.42), 
p = 0.761
0.01 (− 0.04 to 0.06), 
p = 0.761
0.05 (− 0.13 to 0.22), 
p = 0.602
− 0.03 (− 0.18 to 0.13), 
p = 0.726





− 1.18 (− 1.80 to  
− 0.57), p < 0.001
− 2.42a (− 3.17 to  
− 1.67), p < 0.001
− 2.27a (− 2.96 to  
− 1.58), p < 0.001
− 0.35 (− 0.54 to  
− 1.16), p < 0.001
− 1.70a (− 2.24 to  
− 1.17), p < 0.001
Left ventricular end‑
systolic volume index 
(ml/m2.7)
− 0.48 (− 0.84 to  
− 0.12), p = 0.008
− 1.19a (− 1.65 to  
− 0.72), p < 0.001
− 1.10a (− 1.53 to  
− 0.68), p < 0.001
− 0.18 (− 0.29 to  
− 0.07), p = 0.002
− 0.96a (− 1.27 to  




0.042 (0.014 to 0.070), 
p = 0.003
0.007 (0.004 to 0.010), 
p < 0.001
0.025 (0.015 to 0.034), 
p < 0.001
0.013 (0.004 to 0.021), 
p = 0.004




0.037 (0.018 to 0.056), 
p < 0.001
0.006 (0.004 to 0.007), 
p < 0.001
0.020 (0.013 to 0.026), 
p < 0.001
0.012 (0.007 to 0.018), 
p < 0.001
0.000 (0.000 to 0.001), 
p < 0.001
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were compared with persons with normoglycemia, 
besides the smaller LVEDV and LVSV, the LVEF was 
lower and the LVM was higher. A more recent analysis of 
the MESA study [5] demonstrated that IFG and HOMA-
IR were positively associated with LVC. Moreover, in uni-
variate analyses stratified by BMI, subjects with IFG had 
Fig. 1 Adjusted* line (95% CI) showing the associations between fasting glucose (FG) and insulin (FI), the homeostasis model assessment‑insulin 
resistance index (HOMA‑IR) and 2‑h postload glucose (2HG) and insulin (2HI) with left ventricular end‑diastolic volume index (LVEDVI). Adjusted* 
mean (95% CI) LVEDVI according to oral glucose tolerance test (OGTT) classification: normal glucose tolerance (NGT), isolated impaired fasting 
glucose (i‑IFG), isolated impaired glucose tolerance (i‑IGT), combined IFG and IGT (IFG + IGT) and unknown type 2 diabetes (UT2D). *Linear 
regression adjusted for age, sex, body fat‑free mass, body fat mass, systolic blood pressure, use of antihypertensive medication, smoking status, 
alcohol consumption, sedentarism, estimated glomerular filtration rate, fasting time and study sample
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Fig. 2 Adjusted* line (95% CI) showing the associations between fasting glucose (FG) and insulin (FI), the homeostasis model assessment‑insulin 
resistance index (HOMA‑IR) and 2‑h postload glucose (2HG) and insulin (2HI) with left ventricular wall‑thickness index (LVWTI). Adjusted* mean (95% 
CI) LVWTI according to oral glucose tolerance test (OGTT) classification: normal glucose tolerance (NGT), isolated impaired fasting glucose (i‑IFG), 
isolated impaired glucose tolerance (i‑IGT), combined IFG and IGT (IFG + IGT) and unknown type 2 diabetes (UT2D). *Linear regression adjusted 
for age, sex, body fat‑free mass, body fat mass, systolic blood pressure, use of antihypertensive medication, smoking status, alcohol consumption, 
sedentarism, estimated glomerular filtration rate, fasting time and study sample
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Fig. 3 Adjusted* line (95% CI) showing the associations between fasting glucose (FG) and insulin (FI), the homeostasis model assessment‑insulin 
resistance index (HOMA‑IR) and 2‑h postload glucose (2HG) and insulin (2HI) with left ventricular concentricity (LVC). Adjusted* mean (95% CI) LVC 
according to oral glucose tolerance test (OGTT) classification: normal glucose tolerance (NGT), isolated impaired fasting glucose (i‑IFG), isolated 
impaired glucose tolerance (i‑IGT), combined IFG and IGT (IFG + IGT) and unknown type 2 diabetes (UT2D). *Linear regression adjusted for age, sex, 
body fat‑free mass, body fat mass, systolic blood pressure, use of antihypertensive medication, smoking status, alcohol consumption, sedentarism, 
estimated glomerular filtration rate, fasting time and study sample
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Fig. 4 Adjusted* line (95% CI) showing the associations between fasting glucose (FG) and insulin (FI), the homeostasis model assessment‑insulin 
resistance index (HOMA‑IR) and 2‑h postload glucose (2HG) and insulin (2HI) with arterial stiffness index (ASI). Adjusted* mean (95% CI) ASI 
according to oral glucose tolerance test (OGTT) classification: normal glucose tolerance (NGT), isolated impaired fasting glucose (i‑IFG), isolated 
impaired glucose tolerance (i‑IGT), combined IFG and IGT (IFG + IGT) and unknown type 2 diabetes (UT2D). *Linear regression adjusted for age, sex, 
body fat‑free mass, body fat mass, systolic blood pressure, use of antihypertensive medication, smoking status, alcohol consumption, sedentarism, 
estimated glomerular filtration rate, fasting time and study sample
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a higher LVC and LVMI and a lower LVEDVI when com-
pared with individuals with normal fasting glucose.
An investigation of 1603 individuals with a mean age 
of 64 years from the Framingham Heart Study [6], dem-
onstrated positive associations in age-adjusted models 
of HOMA-IR with LVMI, LVC, relative wall thickness, 
LVCO and LVEF for men and women. Noteworthy, 
after further adjustments, that included BMI, just LVC 
remained positively associated with HOMA-IR, while the 
relation with LVMI became even an inverse one.
A previous investigation of the Atherosclerosis Risk in 
Communities (ARIC) study [7] showed that prediabetes 
and type 2 diabetes were associated with higher arte-
rial stiffness when compared with subjects with normal 
glucose levels. A recent study [32] suggests that insulin 
resistance might be an early marker of arterial stiffness 
in healthy and active young to middle-age men. Triglyc-
eride glucose index is the product of fasting plasma glu-
cose and triglycerides and is a strong surrogate for insulin 
resistance [33]. Previous studies found that the triglyc-
eride glucose index was positive associated with the risk 
for incident type 2 diabetes [34] and with arterial stiff-
ness in a relatively healthy Korean population [35] and 
in lean postmenopausal women [33]. Another study [36] 
indicated that lipopolysaccharide-binding protein levels, 
a surrogate of inflammation immune responses, were 
associated with arterial stiffness among male patients 
with type 2 diabetes independently of obesity and tradi-
tional cardiovascular risk factors. Interestingly, treatment 
with liraglutide in patients with recently diagnosed type 2 
diabetes reduced oxidative stress resulting in an improve-
ment of arterial stiffness and left ventricular myocardial 
strain [37]. Moreover, in an experimental model with 
induced type 2 diabetes in female mice, empagliflozin 
improved kidney injury by promoting glycosuria, and 
probably by reducing systemic and renal artery stiffness 
[38].
Finally, our group has previously published findings 
from two independent analyses of KORA FF4 samples. 
The first one [15] which used multivariate models with-
out adjustment for height, weight or BMI, showed that 
individuals with prediabetes and type 2 diabetes had 
lower LVEDV, LVESV, LVSV and higher LVM and LVEF 
(just individuals with prediabetes) when compared with 
subjects with normal glucose metabolism. The second 
one [16], which further adjusted for BMI, showed that 
individuals with prediabetes and type 2 diabetes had 
higher LVWT when compared with subjects with nor-
mal glucose metabolism. We did not find any other MRI 
study regarding LVWT.
All the previously cited studies included MRI deter-
mined heart parameters. The results of our current anal-
yses are, in general, in line with these studies regarding 
the findings of associations of higher glycemic and insu-
lin levels with lower LV cavity size and greater wall thick-
ness, concentricity and arterial stiffness without effect 
on LVCO and LVEF. On the other hand, compared with 
previous studies, we did not find any association of the 
OGTT parameters with LVMI. We believe that the main 
reason for this specific finding was the use of body fat-free 
Table 3 Adjusted* β-coefficient (95% confidence interval [CI]) of  the  associations between  fasting glucose (FG) 
and insulin (FI), the homeostasis model assessment-insulin resistance index (HOMA-IR) and 2-h postload glucose (2HG) 
and  insulin (2HI) with  arterial stiffness index (ASI), left ventricular stroke volume index (LVSI), heart rate (HR), left 
ventricular cardiac output index (LVCI) and left ventricular ejection fraction (LVEF)
Italic values indicate significance of p-value < 0.05
* Linear regression adjusted for age, sex, body fat-free mass, body fat mass, systolic blood pressure, use of antihypertensive medication, smoking status, alcohol 



















β‑coefficient (95% CI), 
p‑value
(n = 984)
Arterial stiffness index 
(mmHg*m2.7/ml)
0.12 (0.06 to 0.17), 
p < 0.001
0.01 (0.00 to 0.01), 
p = 0.011
0.03 (0.01 to 0.05), 
p = 0.002
0.03 (0.01 to 0.04), 
p = 0.005
0.00 (− 0.00 to − 0.00), 
p = 0.870
Left ventricular stroke 
volume index (ml/
m2.7)
− 0.71 (− 1.11 to  
− 0.31), p = 0.001
− 0.07 (− 0.11 to  
− 0.03), p < 0.001
− 0.25 (− 0.38 to  
− 0.11), p < 0.001
− 0.18 (− 0.30 to  
− 0.05), p = 0.006
− 0.84a (− 1.17 to  
− 0.50), p < 0.001
Heart rate (bpm) 2.13 (0.91 to 3.34), 
p = 0.001
4.92a (3.34 to 6.51), 
p < 0.001
4.49a (3.06 to 5.93), 
p < 0.001
0.68 (0.34 to 1.05), 
p < 0.001
0.03 (0.02 to 0.05), 
p < 0.001
Left ventricular cardiac 
output index (l/
min*m2.7)
− 0.02 (− 0.05 to  
− 0.01), p = 0.305
0.00 (− 0.00 to 0.00), 
p = 0.690
0.00 (− 0.01 to 0.01), 
p = 0.875
− 0.00 (− 0.01 to 0.01), 
p = 0.681
− 0.00 (− 0.00 to 0.00), 
p = 0.423
Left ventricular ejection 
fraction (%)
0.01 (− 0.66 to 0.67), 
p = 0.982
0.06 (− 0.00 to 1.13), 
p = 0.061
0.20 (− 0.03 to 0.43), 
p = 0.088
0.10 (− 0.11 to 0.30), 
p = 0.350
0.01 (0.00 to 0.02), 
p = 0.003
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and fat mass, instead of BMI, as covariate (after the initial 
normalization of cardiac parameters to  height2.7). As far 
as we know, almost all previous studies that analyzed the 
associations of glucose and/or insulin levels with cardiac 
structure and function by echocardiography or MRI uti-
lized BMI as a covariate. BIA assess body composition 
Fig. 5 Adjusted* line (95% CI) showing the associations between fasting glucose (FG) and insulin (FI), the homeostasis model assessment‑insulin 
resistance index (HOMA‑IR) and 2‑h postload glucose (2HG) and insulin (2HI) with left ventricular stroke volume index (LVSI). Adjusted* mean (95% 
CI) LVSI according to oral glucose tolerance test (OGTT) classification: normal glucose tolerance (NGT), isolated impaired fasting glucose (i‑IFG), 
isolated impaired glucose tolerance (i‑IGT), combined IFG and IGT (IFG + IGT) and unknown type 2 diabetes (UT2D). *Linear regression adjusted 
for age, sex, body fat‑free mass, body fat mass, systolic blood pressure, use of antihypertensive medication, smoking status, alcohol consumption, 
sedentarism, estimated glomerular filtration rate, fasting time and study sample
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which is considered a better measurement of obesity 
than BMI as it allows to differentiate between fat-free and 
fat mass which both contribute to BMI [39]. In sensitiv-
ity analyses (Additional file  1: Table  S4), we compared 
three regression models of the associations of HOMA-IR 
with LVMI. In the first model, besides the adjustment for 
age, sex, systolic blood pressure, use of antihypertensive 
medication, smoking status, alcohol consumption, seden-
tarism, estimated glomerular filtration rate, fasting time 
and study sample we further adjusted for body fat-free 
and fat mass (our original model). In the second model, 
we did not adjust for fat mass and fat-free-mass, but 
for BMI. Finally, in the third model we further adjusted 
for weight and height. Remarkably, while in our origi-
nal model we had no significant association (p = 0.602), 
it was highly significant, when adjusted for BMI and 
the association was an inverse one (Additional file  1: 
Table  S4). This seems to be the same phenomenon that 
has been observed in the above-discussed analysis of the 
Framingham Heart Study [6]. Actually, we believe that 
adjustment for BMI (which includes height in its calcu-
lation) in a model that included a variable already nor-
malized to  height2.7, might represent an over adjustment 
and thus, potentially, might lead to a misleading result. 
The reason for our choice of body fat-free and fat mass, 
instead of BMI, as cofounders in the multivariate models 
was the potential diverse effects of the different compo-
nents of the body composition. Body fat-free and fat mass 
might have diverse effects on the OGTT parameters and, 
at the same time, the LV structure and function explain-
able by their different structural composition, metabolic 
demands and functional manifestations. Body fat-free 
mass is responsible for almost all of the body’s metabolic 
requirements while body fat mass may be accountable 
for the release of numerous biomarkers and inflamma-
tory cytokines. Moreover, body fat-free mass might have 
a metabolic protective effect that mitigates the excess of 
the previously mentioned markers. We believe that our 
approach to normalize the cardiac parameters to  height2.7 
and subsequent adjust for body fat-free and fat mass was 
the most feasible strategy to analyze the effects of OGTT 
parameters on the heart independently of obesity which 
is highly correlated with both exposures and outcomes.
Potential mechanisms for the observed associations
Glycemic disorders and insulin resistance are usually 
accompanied by several cardiovascular and metabolic 
risk factors and co-morbidities like older age, obesity, 
hypercholesterolemia, hypertension and coronary heart 
disease. Otherwise, the involved pathologic mecha-
nisms that might explain these associations are still 
not completely clarified [2]. Our study protocol was 
not designed to elucidate possible pathophysiological 
mechanisms that might be involved in the associa-
tions described in our analyses and the cross-sectional 
design of our study restricts the evaluation of causal 
relationships. Besides that, there is still no prospective 
clinical trial that had undoubtedly demonstrated that 
higher glucose and insulin levels might have a causal 
association with changes in the heart [2]. Nevertheless, 
we have integrated various risk factors in our multi-
variable regression models. Our results might support 
a direct relation between higher glucose and/or insulin 
levels and greater arterial stiffness, smaller LV chamber 
size and higher LV thickness with resultant LV concen-
tric remodeling and lower LV stroke volume. The LV 
cardiac output would be kept due to higher heart rate.
Dose–response modeling results suggest that fast-
ing glycemic levels do not have a clearly defined 
threshold in their relations with cardiac parameters, 
as with retinopathy, but rather a continuous associa-
tion. Hyperglycemia and hyperinsulinemia are usually 
accompanied by increased free fatty acid levels, sys-
temic and tissue inflammation, oxidative stress, and 
activation of the renin–angiotensin–aldosterone sys-
tem and the sympathetic nervous system. Otherwise, 
the effects of increased glycemic and insulinemic levels 
on the cardiac structure are, in the beginning, clinically 
asymptomatic [2]. These initial effects are character-
ized by higher stiffness (mainly by increased intracel-
lular  Ca2+), increased collagen and advanced glycation 
end products, fibrosis and cellular hypertrophy (mainly 
by expression of hypertrophic genes) [2]. Noteworthy, 
this process should be considered as not specific of the 
heart, but rather of the entire cardio-vascular system. 
Because of this initial process, the LV chamber size 
decreases and the LV wall hypertrophies leading to 
cardiac remodeling, cardiac diastolic dysfunction and 
eventually systolic dysfunction. Our analyses are in line 
with the subclinical presentation of this process.
Finally, one of the possible complications that may 
affect individuals with type 2 diabetes and even with pre-
diabetes is a cardiovascular autonomic neuropathy. This 
condition is characterized by sinus tachycardia, exercise 
intolerance, and orthostatic hypotension [40]. Moreo-
ver, it may also be associated with left ventricular systolic 
and diastolic dysfunction independent of any other car-
diac disease [41]. Interestingly, while the cardiovascular 
autonomic neuropathy might result in a decrease in the 
left ventricular filing volume, leading to a lower stroke 
volume, it also causes sinus tachycardia that will result in 
a normal cardiac output. Unfortunately, our study pro-
tocol did not include measurements, such as heart rate 
variation, the Valsalva maneuver and postural changes 
in blood pressure to evaluate in more detail the cardiac 
autonomic function.
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Study limitations
We need to mention some limitations of our analy-
ses. First, our study sample consisted of European Cau-
casians; therefore, further analyses of samples with 
different ethnicity and age groups would be desirable to 
investigate the strength of this association across those 
groups. Second, the cross-sectional design is a limitation, 
which means that relationships between cause and effect 
might be not recognized. Third, our sample consisted 
of data from two separate studies (SHIP-TREND-0 and 
KORA FF4) with some minor methodological variances 
including difference in sample ages (21 to 81 in SHIP-
TREND-0 and 39 to 73 in KORA FF4). While we con-
sider that this did not have an effect on our results, we 
cannot conclusively exclude it (even after supplementary 
adjustment for study sample in our regression models). 
Finally, although we have incorporated numerous con-
founders into our multivariable regression models, we 
cannot exclude residual confounding due to unmeasured 
conditions.
However, our analyses also have some noteworthy 
strengths, including the large number of subjects based 
on two cohorts of the general population, the standard-
ized evaluation of OGTT data after an overnight fast, and 
the availability of lifestyle data and multiple metabolic 
risk factors.
Conclusions
Our results showed inverse associations of FG (con-
sequence of nocturnal hepatic gluconeogenesis), FI, 
HOMA-IR, 2HG (result of postprandial hyperglycemia) 
and 2HI with LV chamber size. On the other hand, these 
glycemic variables were positively associated with LV 
wall thickness resulting in a LV concentric remodeling 
pattern. Moreover, higher values of the glycemic vari-
ables were also accompanied by greater values of arterial 
stiffness and lower values of LV stroke volume, but not 
with changes in LV cardiac output (since an accompany-
ing higher heart rate) and LV ejection fraction.
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